LNTH vs. ONC, BNTX, TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, and ASND
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Lantheus vs.
Beigene (NASDAQ:ONC) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
Lantheus received 339 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 66.02% of users gave Lantheus an outperform vote while only 60.00% of users gave Beigene an outperform vote.
Lantheus has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Beigene has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.
In the previous week, Lantheus had 21 more articles in the media than Beigene. MarketBeat recorded 25 mentions for Lantheus and 4 mentions for Beigene. Lantheus' average media sentiment score of 0.61 beat Beigene's score of 0.48 indicating that Lantheus is being referred to more favorably in the news media.
48.5% of Beigene shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 7.4% of Beigene shares are held by company insiders. Comparatively, 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Lantheus has a net margin of 28.57% compared to Beigene's net margin of -25.94%. Lantheus' return on equity of 44.29% beat Beigene's return on equity.
Beigene presently has a consensus target price of $310.00, suggesting a potential upside of 22.43%. Lantheus has a consensus target price of $129.43, suggesting a potential upside of 30.16%. Given Lantheus' higher probable upside, analysts clearly believe Lantheus is more favorable than Beigene.
Summary
Lantheus beats Beigene on 13 of the 17 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
This page (NASDAQ:LNTH) was last updated on 3/25/2025 by MarketBeat.com Staff
